Avodart (dutasteride), a new drug for benign prostatic hyperplasia

GlaxoSmithKline is now marketing Avodart (dutasteride), a new drug for benign prostatic hyperplasia.

It's being promoted as better than Proscar (finasteride) because it blocks the two types of 5-alpha reductase.

Proscar selectively blocks only type 2.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote